---
document_datetime: 2025-11-23 11:02:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-zentiva.html
document_name: docetaxel-zentiva.html
version: success
processing_time: 0.1121796
conversion_datetime: 2025-12-28 14:07:27.049321
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Docetaxel Zentiva (previously Docetaxel Winthrop)

[RSS](/en/individual-human-medicine.xml/66726)

##### Withdrawn

This medicine's authorisation has been withdrawn

docetaxel

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Docetaxel Zentiva (previously Docetaxel Winthrop)](#news-on)
- [More information on Docetaxel Zentiva (previously Docetaxel Winthrop)](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 25 April 2022, the European Commission withdrew the marketing authorisation for Docetaxel Zentiva (docetaxel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Zentiva, k.s., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Docetaxel Zentiva was granted marketing authorisation in the EU on 20 April 2007 for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011. Docetaxel Zentiva is identical to Taxotere, which is authorised in the EU to treat breast cancer, nonsmall cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.

The European Public Assessment Report (EPAR) for Docetaxel Zentiva is updated to indicate that the marketing authorisation is no longer valid.

Docetaxel Zentiva : EPAR - Medicine overview

Reference Number: EMA/543296/2019

English (EN) (702.42 KB - PDF)

**First published:** 18/01/2009

**Last updated:** 20/05/2022

[View](/en/documents/overview/docetaxel-zentiva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-213)

български (BG) (793.38 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/bg/documents/overview/docetaxel-zentiva-epar-medicine-overview_bg.pdf)

español (ES) (702.48 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/es/documents/overview/docetaxel-zentiva-epar-medicine-overview_es.pdf)

čeština (CS) (772.4 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/cs/documents/overview/docetaxel-zentiva-epar-medicine-overview_cs.pdf)

dansk (DA) (701.33 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/da/documents/overview/docetaxel-zentiva-epar-medicine-overview_da.pdf)

Deutsch (DE) (704.79 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/de/documents/overview/docetaxel-zentiva-epar-medicine-overview_de.pdf)

eesti keel (ET) (698.73 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/et/documents/overview/docetaxel-zentiva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (802.41 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/el/documents/overview/docetaxel-zentiva-epar-medicine-overview_el.pdf)

français (FR) (703.38 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/fr/documents/overview/docetaxel-zentiva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (724.95 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/hr/documents/overview/docetaxel-zentiva-epar-medicine-overview_hr.pdf)

italiano (IT) (701.05 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/it/documents/overview/docetaxel-zentiva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (784.61 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/lv/documents/overview/docetaxel-zentiva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (725.87 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/lt/documents/overview/docetaxel-zentiva-epar-medicine-overview_lt.pdf)

magyar (HU) (770.98 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/hu/documents/overview/docetaxel-zentiva-epar-medicine-overview_hu.pdf)

Malti (MT) (824.22 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/mt/documents/overview/docetaxel-zentiva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (702.2 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/nl/documents/overview/docetaxel-zentiva-epar-medicine-overview_nl.pdf)

polski (PL) (771.99 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/pl/documents/overview/docetaxel-zentiva-epar-medicine-overview_pl.pdf)

português (PT) (703.09 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/pt/documents/overview/docetaxel-zentiva-epar-medicine-overview_pt.pdf)

română (RO) (723.77 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/ro/documents/overview/docetaxel-zentiva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (771.88 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/sk/documents/overview/docetaxel-zentiva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (1.38 MB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/sl/documents/overview/docetaxel-zentiva-epar-medicine-overview_sl.pdf)

Suomi (FI) (700.26 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/fi/documents/overview/docetaxel-zentiva-epar-medicine-overview_fi.pdf)

svenska (SV) (701.5 KB - PDF)

**First published:**

18/01/2009

**Last updated:**

20/05/2022

[View](/sv/documents/overview/docetaxel-zentiva-epar-medicine-overview_sv.pdf)

Docetaxel Zentiva : EPAR - Risk-management-plan summary

English (EN) (582.71 KB - PDF)

**First published:** 20/12/2019

**Last updated:** 20/05/2022

[View](/en/documents/rmp-summary/docetaxel-zentiva-epar-risk-management-plan-summary_en.pdf)

## Product information

Docetaxel Zentiva : EPAR - Product Information

English (EN) (1.45 MB - PDF)

**First published:** 09/01/2009

**Last updated:** 20/05/2022

[View](/en/documents/product-information/docetaxel-zentiva-epar-product-information_en.pdf)

[Other languages (14)](#file-language-dropdown-740)

български (BG) (7.6 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/bg/documents/product-information/docetaxel-zentiva-epar-product-information_bg.pdf)

español (ES) (1.68 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/es/documents/product-information/docetaxel-zentiva-epar-product-information_es.pdf)

čeština (CS) (5.79 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/cs/documents/product-information/docetaxel-zentiva-epar-product-information_cs.pdf)

dansk (DA) (2.57 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/da/documents/product-information/docetaxel-zentiva-epar-product-information_da.pdf)

Deutsch (DE) (2.28 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/de/documents/product-information/docetaxel-zentiva-epar-product-information_de.pdf)

eesti keel (ET) (3.31 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/et/documents/product-information/docetaxel-zentiva-epar-product-information_et.pdf)

ελληνικά (EL) (7.03 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/el/documents/product-information/docetaxel-zentiva-epar-product-information_el.pdf)

français (FR) (1.89 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/fr/documents/product-information/docetaxel-zentiva-epar-product-information_fr.pdf)

hrvatski (HR) (2.65 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/hr/documents/product-information/docetaxel-zentiva-epar-product-information_hr.pdf)

íslenska (IS) (2.35 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/is/documents/product-information/docetaxel-zentiva-epar-product-information_is.pdf)

italiano (IT) (1.48 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/it/documents/product-information/docetaxel-zentiva-epar-product-information_it.pdf)

lietuvių kalba (LT) (2.91 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/lt/documents/product-information/docetaxel-zentiva-epar-product-information_lt.pdf)

magyar (HU) (4.42 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/hu/documents/product-information/docetaxel-zentiva-epar-product-information_hu.pdf)

Suomi (FI) (2.03 MB - PDF)

**First published:**

09/01/2009

**Last updated:**

20/05/2022

[View](/fi/documents/product-information/docetaxel-zentiva-epar-product-information_fi.pdf)

25/04/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Docetaxel Zentiva (previously Docetaxel Winthrop) : EPAR - All Authorised presentations

English (EN) (589.86 KB - PDF)

**First published:** 15/05/2007

**Last updated:** 20/05/2022

[View](/en/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-409)

български (BG) (652.03 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/bg/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_bg.pdf)

español (ES) (584.39 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/es/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_es.pdf)

čeština (CS) (633.95 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/cs/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (595.43 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/da/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (589.5 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/de/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (603.11 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/et/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (644.34 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/el/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_el.pdf)

français (FR) (590.53 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/fr/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (605.98 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/hr/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (668.74 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/is/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_is.pdf)

italiano (IT) (583.01 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/it/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (645.7 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/lv/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (607.99 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/lt/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (625.39 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/hu/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (626.11 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/mt/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (583.37 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/nl/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (589.54 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/no/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_no.pdf)

polski (PL) (634.45 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/pl/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_pl.pdf)

português (PT) (583.9 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/pt/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_pt.pdf)

română (RO) (626.85 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/ro/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (652.91 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/sk/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (1.18 MB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/sl/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (593.77 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/fi/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (620.94 KB - PDF)

**First published:**

15/05/2007

**Last updated:**

20/05/2022

[View](/sv/documents/all-authorised-presentations/docetaxel-zentiva-previously-docetaxel-winthrop-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Docetaxel Zentiva (previously Docetaxel Winthrop) Active substance docetaxel International non-proprietary name (INN) or common name docetaxel Therapeutic area (MeSH)

- Head and Neck Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Prostatic Neoplasms
- Stomach Neoplasms
- Breast Neoplasms

Anatomical therapeutic chemical (ATC) code L01CD02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Breast cancer**

Docetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:

- operable node-positive breast cancer;
- operable node-negative breast cancer.

For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.

Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.

Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.

Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.

Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.

**Non-small-cell lung cancer**

Docetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.

Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.

**Prostate cancer**

Docetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.

**Gastric adenocarcinoma**

Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.

**Head and neck cancer**

Docetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

## Authorisation details

EMA product number EMEA/H/C/000808 Marketing authorisation holder

Zentiva k.s.

U kabelovny 130

Marketing authorisation issued 20/04/2007 Revision 30

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Docetaxel Zentiva (previously Docetaxel Winthrop) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (826.02 KB - PDF)

**First published:** 16/01/2009

**Last updated:** 20/05/2022

[View](/en/documents/procedural-steps-after/docetaxel-zentiva-previously-docetaxel-winthrop-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Docetaxel Zentiva-H-C-WS1550 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/647024/2019

English (EN) (4.69 MB - PDF)

**First published:** 20/12/2019

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/docetaxel-zentiva-h-c-ws1550-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Docetaxel Zentiva (WS-1550)

Adopted

Reference Number: EMA/CHMP/510410/2019

English (EN) (630.87 KB - PDF)

**First published:** 20/09/2019

**Last updated:** 20/05/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-zentiva-ws-1550_en.pdf)

Docetaxel Winthrop- H-C-PSUSA-00001152-201611 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/841571/2017

English (EN) (625.33 KB - PDF)

**First published:** 20/12/2017

**Last updated:** 20/05/2022

[View](/en/documents/scientific-conclusion/docetaxel-winthrop-h-c-psusa-00001152-201611-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Docetaxel Winthrop-H-C-808-P46-0011 : EPAR - Assessment Report

Adopted

Reference Number: EMA/89165/2013

English (EN) (656.82 KB - PDF)

**First published:** 14/02/2013

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/docetaxel-winthrop-h-c-808-p46-0011-epar-assessment-report_en.pdf)

Docetaxel Winthrop-H-C-808-II-0012 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/449127/2010

English (EN) (1.7 MB - PDF)

**First published:** 30/07/2010

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/docetaxel-winthrop-h-c-808-ii-0012-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Docetaxel Winthrop

Adopted

English (EN) (624.18 KB - PDF)

**First published:** 21/05/2010

**Last updated:** 20/05/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-winthrop_en.pdf-0)

Docetaxel Winthrop-H-C-808-X-0008 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/774985/2009

English (EN) (625.08 KB - PDF)

**First published:** 04/02/2010

**Last updated:** 20/05/2022

[View](/en/documents/variation-report/docetaxel-winthrop-h-c-808-x-0008-epar-assessment-report-extension_en.pdf)

CHMP post-authorisation summary of positive opinion for Docetaxel Winthrop

Adopted

Reference Number: EMEA/CHMP/752754/2009

English (EN) (594.38 KB - PDF)

**First published:** 19/11/2009

**Last updated:** 20/05/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-docetaxel-winthrop_en.pdf)

Docetaxel Winthrop-H-C-808-II-0001 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (1.25 MB - PDF)

**First published:** 25/11/2008

**Last updated:** 20/05/2022

[View](/en/documents/scientific-discussion-variation/docetaxel-winthrop-h-c-808-ii-0001-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Docetaxel Winthrop : EPAR - Scientific Discussion

English (EN) (610.07 KB - PDF)

**First published:** 15/05/2007

**Last updated:** 20/05/2022

[View](/en/documents/scientific-discussion/docetaxel-winthrop-epar-scientific-discussion_en.pdf)

Docetaxel Winthrop : EPAR - Procedural steps taken before authorisation

English (EN) (593.75 KB - PDF)

**First published:** 15/05/2007

**Last updated:** 20/05/2022

[View](/en/documents/procedural-steps/docetaxel-winthrop-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Docetaxel Zentiva (previously Docetaxel Winthrop)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019) 20/09/2019

[PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel](/en/news/prac-concludes-there-no-evidence-change-known-risk-neutropenic-enterocolitis-docetaxel) 09/06/2017

#### More information on Docetaxel Zentiva (previously Docetaxel Winthrop)

- [Docetaxel Zentiva (previously Docetaxel Winthrop) - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/docetaxel-zentiva-previously-docetaxel-winthrop)

**This page was last updated on** 20/05/2022

## Share this page

[Back to top](#main-content)